Diligence memo · auto-generated · as of July 2, 2026
Omeros Corp
Omeros Corp looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Omeros Corp operates in Biotechnology, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Omeros Corp has raised $52M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $40M on —.
Valuation (modeled)modeled
Provath models Omeros Corp at approximately $121M (range $80M–$148M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.38× the median modeled value of Series B Biotechnology companies (659 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
No dated round to assess.
The last round stepped up 3.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotechnology peers (4293 compared).
Modeled value ranks above 62% of those peers.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.